Cargando…
Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation
BACKGROUND: Swallowing tablets/capsules can become difficult and dangerous for People with Parkinson’s (PwP) who develop oropharyngeal dysphagia. Switching to a liquid delays the need for progressing to last line patches/injections. However, liquids are rarely used therefore a change in prescribing...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393141/ https://www.ncbi.nlm.nih.gov/pubmed/35842516 http://dx.doi.org/10.1007/s11096-022-01446-z |
_version_ | 1784771205769723904 |
---|---|
author | Atkins, Bethany Bhattacharya, Debi Smith, Caroline Scott, Sion |
author_facet | Atkins, Bethany Bhattacharya, Debi Smith, Caroline Scott, Sion |
author_sort | Atkins, Bethany |
collection | PubMed |
description | BACKGROUND: Swallowing tablets/capsules can become difficult and dangerous for People with Parkinson’s (PwP) who develop oropharyngeal dysphagia. Switching to a liquid delays the need for progressing to last line patches/injections. However, liquids are rarely used therefore a change in prescribing practice is warranted but, as with any change in behaviour, may be met with resistance. AIM: To characterise PwPs and carers’ barriers and enablers (determinants) of switching from solid to liquid Parkinson’s medication formulations. METHOD: Underpinned by the Theoretical Domains Framework, focus groups with PwPs and carers were convened to identify determinants of switching, which were then used to develop a questionnaire distributed across the UK. Determinants were prioritised if ≥ 50% of respondents agreed/strongly agreed that they were important to their decision to switch to a liquid formulation. Percentage precisions were reported as 95% confidence intervals. RESULTS: From three focus groups and 131 questionnaires responses, PwPs and carers prioritised nine determinants. Three enablers had almost unanimous agreement: liquids’ flexibility for incremental dosing (72% ± 8); decline in Parkinson’s control (72% ± 8); prescriber’s endorsement to switch (70% ± 8). The barriers: perception that tablets/capsules are easier to dose than liquids (72% ± 8); and prescriber’s opposition to switching (70% ± 8), attracted similarly high agreement. CONCLUSION: There is a desire to switch to liquids when Parkinson’s progresses and for their use beyond this to offer flexibility in dosing, a previously unrecognised indication for switching. The only notable resistance to switching may be addressed by innovations from the pharmaceutical industry to make liquids easier to measure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11096-022-01446-z. |
format | Online Article Text |
id | pubmed-9393141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-93931412022-08-23 Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation Atkins, Bethany Bhattacharya, Debi Smith, Caroline Scott, Sion Int J Clin Pharm Research Article BACKGROUND: Swallowing tablets/capsules can become difficult and dangerous for People with Parkinson’s (PwP) who develop oropharyngeal dysphagia. Switching to a liquid delays the need for progressing to last line patches/injections. However, liquids are rarely used therefore a change in prescribing practice is warranted but, as with any change in behaviour, may be met with resistance. AIM: To characterise PwPs and carers’ barriers and enablers (determinants) of switching from solid to liquid Parkinson’s medication formulations. METHOD: Underpinned by the Theoretical Domains Framework, focus groups with PwPs and carers were convened to identify determinants of switching, which were then used to develop a questionnaire distributed across the UK. Determinants were prioritised if ≥ 50% of respondents agreed/strongly agreed that they were important to their decision to switch to a liquid formulation. Percentage precisions were reported as 95% confidence intervals. RESULTS: From three focus groups and 131 questionnaires responses, PwPs and carers prioritised nine determinants. Three enablers had almost unanimous agreement: liquids’ flexibility for incremental dosing (72% ± 8); decline in Parkinson’s control (72% ± 8); prescriber’s endorsement to switch (70% ± 8). The barriers: perception that tablets/capsules are easier to dose than liquids (72% ± 8); and prescriber’s opposition to switching (70% ± 8), attracted similarly high agreement. CONCLUSION: There is a desire to switch to liquids when Parkinson’s progresses and for their use beyond this to offer flexibility in dosing, a previously unrecognised indication for switching. The only notable resistance to switching may be addressed by innovations from the pharmaceutical industry to make liquids easier to measure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11096-022-01446-z. Springer International Publishing 2022-07-16 2022 /pmc/articles/PMC9393141/ /pubmed/35842516 http://dx.doi.org/10.1007/s11096-022-01446-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Atkins, Bethany Bhattacharya, Debi Smith, Caroline Scott, Sion Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation |
title | Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation |
title_full | Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation |
title_fullStr | Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation |
title_full_unstemmed | Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation |
title_short | Barriers and enablers to switching from a solid to a liquid formulation of Parkinson’s medication: a theory-based mixed methods investigation |
title_sort | barriers and enablers to switching from a solid to a liquid formulation of parkinson’s medication: a theory-based mixed methods investigation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393141/ https://www.ncbi.nlm.nih.gov/pubmed/35842516 http://dx.doi.org/10.1007/s11096-022-01446-z |
work_keys_str_mv | AT atkinsbethany barriersandenablerstoswitchingfromasolidtoaliquidformulationofparkinsonsmedicationatheorybasedmixedmethodsinvestigation AT bhattacharyadebi barriersandenablerstoswitchingfromasolidtoaliquidformulationofparkinsonsmedicationatheorybasedmixedmethodsinvestigation AT smithcaroline barriersandenablerstoswitchingfromasolidtoaliquidformulationofparkinsonsmedicationatheorybasedmixedmethodsinvestigation AT scottsion barriersandenablerstoswitchingfromasolidtoaliquidformulationofparkinsonsmedicationatheorybasedmixedmethodsinvestigation |